Toripalimab
Toripalimab is a humanized anti-PD-1 monoclonal antibody that blocks the PD-1/PD-L1 checkpoint interaction, restoring anti-tumor T-cell responses and reversing immune exhaustion in the tumor microenvironment. It is approved in China and the US for relapsed or metastatic nasopharyngeal carcinoma and is under investigation for multiple other malignancies including melanoma and hepatocellular carcinoma. Its development as a PD-1 checkpoint inhibitor follows the same immune checkpoint blockade strategy as pembrolizumab and nivolumab.
Áreas terapéuticas
Mecanismo de acción
As a monoclonal antibody, it binds with high specificity to its target antigen, modulating the immune response through mechanisms including receptor blockade, immune cell engagement, or targeted cytotoxicity.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
As a monoclonal antibody, it binds with high specificity to its target antigen, modulating the immune response through mechanisms including receptor blockade, immune cell engagement, or targeted cytotoxicity.
HBD / HBA
- / -
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Preguntas frecuentes
Toripalimab is a humanized anti-PD-1 monoclonal antibody that blocks the PD-1/PD-L1 checkpoint interaction, restoring anti-tumor T-cell responses and reversing immune exhaustion in the tumor microenvironment. It is approved in China and the US for relapsed or metastatic nasopharyngeal carcinoma and is under investigation for multiple other malignancies including melanoma and hepatocellular carcinoma. Its development as a PD-1 checkpoint inhibitor follows the same immune checkpoint blockade strategy as pembrolizumab and nivolumab.
As a monoclonal antibody, it binds with high specificity to its target antigen, modulating the immune response through mechanisms including receptor blockade, immune cell engagement, or targeted cytotoxicity.
Yes, Toripalimab is an approved drug. It has reached clinical phase 4. It is classified as a Antibody.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL4297843. Open-access bioactivity database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="toripalimab"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/toripalimab/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/toripalimab/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/toripalimab/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="toripalimab"></drugfyi-drug>